Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cenomed BioSciences to Present at 9th SoCalBio Investor Conference.


IRVINE, Calif. -- Cenomed BioSciences, LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
, a privately-held biopharmaceutical company focused on the development of innovative new drug therapies for the treatment of nervous system disorders Nervous system disorders

A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency
, today announced that David R. Helton, president and chief scientific officer, will present a company overview at the SoCalBio Investor Conference (Southern California Biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 Council) on June 7, 2007 at the Wilshire Grand Hotel, Downtown Los Angeles Downtown Los Angeles is the central business district of Los Angeles, California, located close to the geographic center of the metropolitan area. The sprawling, multi-centered megacity is such that its downtown core is often considered just another district like Hollywood or , California.

Organized once a year by the Southern California Biomedical Council, the SoCalBio Investor Conference features business presentations by CEOs of Southern California device, pharmaceutical and e-health firms interested in raising capital and/or forging strategic partnerships. It also offers forums to engage technologists and investors in a discourse over new models of commercializing life-science innovations.

Interested parties can see company presentation times and learn more about the conference at www.socalbio.org.

About Cenomed BioSciences, LLC

Cenomed BioSciences, LLC is a privately-held biopharmaceutical company focused on the development of innovative new drug therapies for neuroprotection, chemical defense and the treatment of nervous system disorders such as schizophrenia, mild cognitive impairment mild cognitive impairment (MCI),
n memory loss generally associated with aging; does not affect normal independent functioning of an individual.
 and memory/attention impairments associated with aging, attention deficit hyperactivity disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity.  and pain. More information on Cenomed BioSciences is available at www.cenomedbiosciences.com.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 4, 2007
Words:197
Previous Article:Hercules Provides $10 Million of Venture Debt to EKOS Corporation, a Developer of Ultrasound-accelerated Drug Therapy Devices.
Next Article:Computing Technology Industry Association Recognizes Three Organizations for Their Support of CompTIA CDIA+ Certification.
Topics:



Related Articles
Amarillo Biosciences Attends Texas Biomedical Investment Conference.
Nearly A Dozen Companies, Two Analysts Highlight Second Boston Biotechnology Stocks Forum June 7.
MedImmune, Inhale Therapeutics Head Up Third Beltway Biotech Stocks Forum In Tyson's Corner June 5.
Sonus Pharmaceuticals to Present at Upcoming Investor Conferences.
Celsion Corporation to Present at the NYSSA 9th Annual Biotech/Specialty Pharma Conference.
Hana Biosciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference.
Preclinical Data on Cytogen's Technology to be Reported at the AACR Annual Meeting.
Cytogen Reports Publication Validating the Utility of its Proprietary ProChart(TM) Database.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles